^
Association details:
| Biomarker: | MPZL3 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | saracatinib (AZD0530) (Src kinase inhibitor, FAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A systemic pan-cancer analysis of MPZL3 as a potential prognostic biomarker and its correlation with immune infiltration and drug sensitivity in breast cancer
Published date:
07/29/2022
Excerpt:
Cell proliferation and drug sensitivity tests were applied to analyze the biological role of MPZL3 and drug sensitivities in breast cancer....In contrast, the group with higher MPZL3 expression was more sensitive to lapatinib, erlotinib, and ZD-6474, which specifically target EGFR, more sensitive to AZD0530, which targets ABL, and more sensitive to TKI258, which targets FGFR.
DOI:
10.3389/fonc.2022.901728
